Clinical-stage biopharmaceutical company
Appears in 1 story
Licensed CUE-221 in April 2026; now planning Phase 2b/3
Cue Biopharma's experimental chronic hives drug hit its primary goal in a 145-patient Phase 2 trial, clearing the way for a registration-enabling study. At the highest dose, CUE-221 produced complete resolution of hives in 54% of patients at week 12, versus 11% on placebo.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
